Oleclumab - AstraZeneca
Alternative Names: Anti-CD73 MAb; Anti-CD73 monoclonal antibody; MEDI-9447Latest Information Update: 19 Jul 2024
At a glance
- Originator MedImmune
- Developer AstraZeneca; European Network of Gynaecological Oncological Trial Groups; Jules Bordet Institute; M. D. Anderson Cancer Center; MedImmune; National Cancer Institute (USA)
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
- Phase I/II Colorectal cancer
- No development reported Bladder cancer; Solid tumours
Most Recent Events
- 31 May 2024 Adverse events and efficacy data from a phase II COAST trial in Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 05 Apr 2024 Pharmacodynamics data from the phase II NeoCOAST trial in Non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 04 Oct 2023 University Health Network plans a phase II trial for Pancreatic Cancer (IV) in October 2023 (NCT06060405)